Raw materials for medicines imported from China are stuck at ports and airports will impact the production of key Covid-19 drugs, Remdesivir and Favipiravir. The delay in clearance of consignments of key chemicals used to produce advanced pharmaceutical ingredients (APIs) and formulations for lifesaving Covid-19 drugs, will impact the drugs’ production schedule, which is critical in the present scenario. critical raw material and bulk drugs are imported from China, with the country accounting for nearly 70% of API (active pharmaceutical imports), while in certain cases like antibiotics, the dependence is around 90%.